aripiprazole has been researched along with Psychoses in 298 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 125 (41.95) | 29.6817 |
2010's | 132 (44.30) | 24.3611 |
2020's | 41 (13.76) | 2.80 |
Authors | Studies |
---|---|
Cui, H; Hu, Y; Li, C; Ling, Z; Tang, X; Tang, Y; Wang, J; Wei, Y; Xu, L; Zhang, T | 1 |
Abler, V; Rajagopalan, K; Rashid, N; Yunusa, I | 1 |
Dragovic, M; Hacking, D; Hulme, D; Parmar, A; Shymko, G; Terina, G; Waters, F | 1 |
Correll, CU; Decara, MS; Fagerlund, B; Fink-Jensen, A; Galling, B; Jensen, KG; Jeppesen, P; Jepsen, JRM; Klauber, DG; Krogmann, A; Pagsberg, AK; Rudå, D; von Hardenberg, L | 1 |
Kim, SG; Seo, EH; Yang, HJ; Yoon, HJ | 1 |
Alisauskiene, R; Fathian, F; Fleichhacker, WW; Gjestad, R; Joa, I; Johnsen, E; Kjelby, E; Kroken, RA; Larsen, TK; Løberg, EM; Reitan, SK; Rettenbacher, M; Sinkevicute, I; Stabell, LA; Steen, VM | 1 |
Kam, O; Koola, MM; Lee, G; Reinfeld, S; Russell, G; Weiss, M | 1 |
Kashihara, K; Maeda, T; Yoshida, K | 1 |
Abler, VC; Demos, GN; Mahadik, BS; Rajagopalan, K; Rashid, N; Yunusa, I | 1 |
Chen, T; Gan, R; Hu, Y; Li, C; Raballo, A; Tang, X; Tang, Y; Wang, J; Wei, Y; Wu, G; Xu, L; Zeng, J; Zhang, T | 1 |
Di Lorenzo, G; Jannini, EA; Jannini, TB; Rossi, R; Sansone, A; Siracusano, A; Toscano, M | 1 |
Broberg, BV; Ebdrup, BH; Glenthøj, BY; Lykkesfeldt, J; Myken, AN; Nielsen, MØ; Skjerbæk, MW; Sørensen, ME | 1 |
Crespo-Facorro, B; Garrido-Torres, N; Gómez-Revuelta, M; Juncal-Ruiz, M; Mayoral-van Son, J; Ortiz-García de la Foz, V; Vázquez-Bourgon, J | 1 |
De Ronchi, D; Fabbri, C; Fanelli, G; Lippi, M; Serretti, A | 1 |
Ayesa-Arriola, R; Crespo-Facorro, B; Garrido-Sánchez, L; Gómez-Revuelta, M; Juncal-Ruiz, M; Mayoral-Van Son, J; Ortiz-García de la Foz, V; Pelayo-Terán, JM; Ruiz-Veguilla, M; Vázquez-Bourgon, J | 1 |
Chien, YL; Hsieh, MH; Hwang, TJ; Hwu, HG; Lin, YT; Liu, CC; Liu, CM | 1 |
Ando, Y; Hisano, T; Kanamura, S; Maeda, K; Matsuzaka, Y; Morimoto, Y; Noguchi, M; Otsuka, T; Ozawa, H; Tanaka, D; Yamamoto, T | 1 |
Davies, SJ; Nutt, DJ; Zhou, C | 1 |
Bartolomei, G; Gambaro, E; Gramaglia, C; Lorenzini, L; Martelli, M; Zeppegno, P | 1 |
Acacio, MC; Dobson, L; Grace, T; Shymko, G; Tadier, S; Waters, F | 1 |
Bechdolf, A; de Millas, W; Falkai, P; Gaebel, W; Gallinat, J; Hasan, A; Heinz, A; Hellmich, M; Janssen, B; Juckel, G; Karow, A; Klosterkötter, J; Krüger-Özgürdal, S; Lambert, M; Maier, W; Meyer-Lindenberg, A; Müller, H; Pützfeld, V; Rausch, F; Schneider, F; Stützer, H; Wagner, M; Wobrock, T; Zink, M | 1 |
Dudek, D; Heitzman, J; Janas-Kozik, M; Remberk, B; Samochowiec, J; Słopień, A; Wichniak, A | 1 |
Abdel-Baki, A; Béchard, L; Brodeur, S; Corbeil, O; Demers, MF; Desmeules, C; Dorval, M; Essiambre, AM; Fournier, É; Giroux, I; Huot-Lavoie, M; Jacques, C; Roy, MA; Soulard, M; Thériault, C | 1 |
Juza, R; Kelemen, E; Korabecny, J; Petrasek, T; Soukup, O; Stuchlik, A; Tuckova, K; Vojtechova, I | 1 |
Iyo, M; Kanahara, N; Kimura, H; Kogure, M; Koyoshi, S; Nakata, Y; Oiwa, T; Saito, T; Sasaki, T; Yamasaki, F; Yanagisawa, Y; Yoshida, T | 1 |
Foreman, K; Loh, R; Thurstone, C; Thurstone, CA; Wolf, C | 1 |
Buckle, J; Forshall, E; Harris, M; Kavanagh, G; Murphy, T; Pereira, M; Thompson, A; Whale, R; Wilson, M | 1 |
Iyer, S; Joober, R; Lepage, M; Malla, A; Mustafa, S; Shah, J | 1 |
Garel, N; Joober, R | 1 |
Ayesa-Arriola, R; Crespo-Facorro, B; Gómez-Revuelta, M; Juncal-Ruiz, M; Pelayo-Terán, JM; Romero-Jiménez, R; Setién Suero, E; Suárez-Pinilla, P; Vázquez-Bourgon, J | 1 |
Shad, MU; Yeager, A | 1 |
Economou, M; Kontoangelos, K; Lazaratou, E; Papageorgiou, CC; Yiannopoulou, KG | 1 |
Crespo-Facorro, B; García-Rizo, C; González-Rodríguez, A; Labad, J; Monreal, JA; Montalvo, I; Palao, D | 1 |
Du, Y; Hard, M; Marandi, M; von Moltke, L; Walling, DP; Wehr, A; Weiden, PJ | 1 |
Dobson, L; Grace, T; Hacking, D; Jolly, N; Kapi, P; Parmar, A; Shymko, G; Waters, F | 1 |
Ayesa Arriola, R; Crespo Facorro, B; Gómez Revuelta, M; Ibáñez Alario, M; Juncal Ruiz, M; Mayoral-van Son, J; Ortiz-García de la Foz, V; Vázquez-Bourgon, J | 1 |
Alisauskiene, R; Anda, LG; Bartz-Johannessen, C; Berle, JØ; Bjarke, J; Fathian, F; Fleischhacker, WW; Hugdahl, K; Joa, I; Johnsen, E; Kjelby, E; Kroken, RA; Larsen, TK; Løberg, EM; Reitan, SK; Rettenbacher, M; Sinkeviciute, I; Skrede, S; Stabell, L; Steen, VM; Walla, B | 1 |
Likhitsathian, S; Maneeton, B; Maneeton, N; Oon-Arom, A; Srisurapanont, M; Suradom, C; Suttajit, S | 1 |
Barbui, C; Bertolini, F; Bovo, C; Correll, CU; Del Giovane, C; Gastaldon, C; Nosé, M; Ogheri, F; Ostuzzi, G; Papola, D; Purgato, M; Tedeschi, F; Turrini, G | 1 |
Ayesa-Arriola, R; Crespo-Facorro, B; Gómez-Revuelta, M; Mayoral-van Son, J; Ortiz-García de la Foz, V; Pelayo-Terán, JM; Vázquez-Bourgon, J | 1 |
Carmichael, PH; Corbeil, O; Corbeil, S; Demers, MF; Dorval, M; Giroux, I; Jacques, C; Roy, MA | 1 |
Ayesa-Arriola, R; Crespo-Facorro, B; Ortiz-García de la Foz, V; Setién-Suero, E; Suárez-Pinilla, P | 1 |
Alba, L; Alonso, L; Coll, C; Ortiz, S; Palma, S; Pérez, H; Sáez, S; Vallés, V | 1 |
Baker, RA; Eramo, A; Hertel, P; Ismail, Z; Jin, N; Kane, JM; McQuade, RD; Miguelez, M; Perry, P; Peters-Strickland, T; Sanchez, R | 1 |
Crespo-Facorro, B; Gomez-Arnau, J; Juncal-Ruiz, M; Martinez-Garcia, O; Neergaard, KD; Ortiz-Garcia de la Foz, V; Ramirez-Bonilla, M; Suarez-Pinilla, P; Tabares-Seisdedos, R | 1 |
Hard, ML; Mills, RJ; Sadler, BM; von Moltke, L; Wehr, AY; Weiden, PJ | 1 |
Bilenberg, N; Correll, CU; Fagerlund, B; Fink-Jensen, A; Gluud, C; Jantzen, P; Jensen, KG; Jeppesen, P; Jepsen, JRM; Klauber, DG; Lange, T; Lauritsen, MG; Madsen, S; Nyvang, L; Pagsberg, AK; Rasmussen, S; Rudå, D; Saldeen, EA; Skoog, M; Stenstrøm, AD; Stentebjerg-Olesen, M; Werge, TM; Winkel, P | 1 |
Bishop, JR; Brown, JT; Eum, S; Lee, AM; Schneiderhan, ME | 1 |
Nesvåg, R | 1 |
de Haan, L; Schulte, PFJ; Veerman, SRT | 1 |
Lee, C; Shen, YC | 1 |
Baker, RA; Carson, W; Correll, CU; Kohegyi, E; McQuade, R; Nyilas, M; Salzman, PM; Sanchez, R; Zhao, C | 1 |
Brunet, M; Espinosa-Martínez, L; Fortea, A; Fortuna, V; González-Rodríguez, A; Oriolo, G; Parellada, E | 1 |
Crespo-Facorro, B; Díaz Martínez, Á; Ortiz-García de la Foz, V; Pérez-Iglesias, R; Suárez Pinilla, P; Vázquez-Bourgon, J | 1 |
Correll, CU; Fagerlund, B; Fink-Jensen, A; Gärtner, S; Jensen, KG; Jepsen, JR; Juul, K; Klauber, DG; Pagsberg, AK; Rudå, D; Stentebjerg-Olesen, M | 1 |
Vohra, A | 1 |
Chan, CH; Chan, HY; Chen, YC | 1 |
Bramness, JG; Handal, M; Hartz, I; Hjellvik, V; Nesvåg, R; Skurtveit, S | 1 |
Baeza, I; de Castro, C; Espinosa, L; Fortea, A; Ilzarbe, D; Oriolo, G; Solerdelcoll, M; Sugranyes, G | 1 |
Aoki, S; Harada, T; Kishi, Y; Nomura, A; Sato, K; Takeda, T; Washida, K; Yada, Y; Yoshimura, B; Yoshimura, Y | 1 |
Gastaldon, C; Ostuzzi, G; Papola, D | 1 |
Barreto, S; Kar, N | 1 |
Bateman, BT; Cohen, JM; Cohen, LS; Desai, RJ; Glynn, RJ; Hernandez-Diaz, S; Huybrechts, KF; Mogun, H; Park, Y; Patorno, E | 1 |
Ballerini, A; Brugnoli, R; Carrus, D; Comparelli, A; De Filippis, S; Del Casale, A; Ducci, G; Francomano, A; Girardi, P; Kotzalidis, GD; Mancinelli, I; Marcellusi, A; Mennini, FS; Pompili, M; Rapinesi, C; Sani, G; Sorice, S; Splendori, F; Trovini, G; Verzura, C | 1 |
Adams, HA; Buchanan, RW; Buckley, PF; Dickerson, FB; Earl, AK; Feldman, SM; Hackman, AL; Kearns, AM; Kelly, DL; Koola, MM; Liu, F; Luttrell, SE; McEvoy, JP; McMahon, RP; Narang, S; Nichols, RB; Powell, MM; RachBeisel, JA; Richardson, CM; Sayer, MA; Sullivan, KM; Vyas, G; Wehring, HJ | 1 |
Crespo-Facorro, B; Juncal-Ruiz, M; Leza, JC; López-Hoyos, M; Martínez-Garcia, O; Ocejo-Viñals, JG; Ortiz-García de la Foz, V; Ramírez-Bonilla, M; Riesco-Dávila, L | 1 |
Ayesa-Arriola, R; Crespo-Facorro, B; Gimenez-Donoso, S; Setien-Suero, E; Tirapu-Ustarroz, J; Treen-Calvo, D | 1 |
Fryefield, K; Shad, MU | 1 |
Crespo-Facorro, B; Gómez-Revuelta, M; González-Pinto, A; Juncal-Ruiz, M; Ortiz-García de la Foz, V; Pelayo-Terán, JM; Vázquez-Bourgon, J | 1 |
Dias Alves, M; Micoulaud-Franchi, JA; Simon, N; Vion-Dury, J | 1 |
Azorin, JM; Simon, N | 1 |
Gehrmann, J; Götz Lampe, P | 1 |
Beex-Oosterhuis, MM; Dieleman, HG; Eussen, MLJM; Schoemakers, RJ; van Kesteren, C; van Rosmalen, J | 1 |
Andreescu, N; Grădinaru, R; Nussbaum, L; Puiu, M; Suciu, L | 1 |
Kahn, DA | 1 |
Correll, CU; Decara, MS; Eriksson, F; Fagerlund, B; Fink-Jensen, A; Jensen, KG; Jepsen, JRM; Klauber, DG; Pagsberg, AK; Rudå, D | 1 |
Edelsohn, GA | 1 |
Haslemo, T; Ingelman-Sundberg, M; Jukic, MM; Molden, E; Smith, RL | 1 |
Cope, N; Fowler, JC; Knights, J; Makin, A; Peters-Strickland, T; Phiri, P; Rathod, S | 1 |
Chouinard, G; Peretti, CS | 1 |
Ayesa-Arriola, R; Crespo-Facorro, B; Mata, I; Ortiz-García de la Foz, V; Pérez-Iglesias, R; Suarez-Pinilla, P; Valdizan, EM; Vázquez-Barquero, JL | 1 |
Edlinger, M; Fleischhacker, W; Hofer, A; Seppi, K | 1 |
Alnıak, İ; Ulusoy, S; Yavuz, KF | 1 |
Remington, G; Takeuchi, H | 1 |
Chen, CK; Chou, MC; Chou, WJ; Huang, YS; Tang, CS; Wang, LJ; Yeh, CB | 1 |
Ayesa-Arriola, R; Crespo-Facorro, B; de la Foz, VO; Martinez-Garcia, O; Mata, I; Pérez-Iglesias, R; Suarez-Pinilla, P; Valdizan, EM | 1 |
Cho, DH; Chung, YC; Hahn, SW; Jeong, B; Kim, JH; Kim, SW; Koo, MS; Lee, SH; Lee, SJ; Lee, YH; Park, JI; Rho, SH | 1 |
Datta, SS; Furtado, VA; Kumar, A; Russell, PS; Wright, SD | 1 |
Alcera, E; Coffey, DB; Patel, S; Tosyali, PM; Varas, DB | 1 |
Gallego, JA; Ikuta, T; Kane, J; Malhotra, AK; Peters, BD; Robinson, DG; Szeszko, PR | 1 |
Eleméry, M; Faludi, G; Kovács, G; Szegő, A | 1 |
Eatt, J; Varghese, ST | 1 |
Aguglia, E; Bianchini, O; Cannavò, D; De Ronchi, D; Nespeca, C; Porcelli, S; Serretti, A; Trappoli, A | 1 |
Bruno, A; Muscatello, MR; Pandolfo, G; Romeo, VM; Scimeca, G; Zoccali, RA | 1 |
Makkos, Z | 1 |
Bilenberg, N; Correll, CU; Fagerlund, B; Fink-Jensen, A; Gluud, C; Jantzen, P; Jensen, KG; Jeppesen, P; Jepsen, JR; Juul, K; Klauber, DG; Lauritsen, MB; Madsen, S; Nyvang, L; Pagsberg, AK; Paludan, J; Pedersen, J; Rasmussen, S; Rudå, D; Saldeen, EA; Skoog, M; Stenstrøm, AD; Stentebjerg-Olesen, M; Thomsen, PH; Vernal, DL; Werge, TM; Wetterslev, J; Winge, K | 1 |
Morrissette, DA; Stahl, SM | 1 |
Gentile, S | 1 |
Amado, JA; Ayesa-Arriola, R; Crespo-Facorro, B; Garcia-Unzueta, MT; Martínez García, O; Ortiz-Garcia de la Foz, V; Pérez-Iglesias, R; Suarez-Pinilla, P; Tabares-Seisdedos, R | 1 |
Argyelan, M; Gallego, JA; Ikuta, T; Kane, JM; Karlsgodt, K; Lencz, T; Malhotra, AK; Robinson, DG; Sarpal, DK; Szeszko, PR | 1 |
Calabrò, G; Caloro, M; Cuomo, I; De Filippis, S; Girardi, P; Kotzalidis, GD; Ranieri, V; Telesforo, CL; Zingaretti, P | 1 |
Jarvis, GE; Margolese, HC; Propst, AJ | 1 |
Connolly, JG; Schneeweiss, MC; Toomey, TJ | 1 |
Álamo, C; Bernardo, M; Bobes, J; Hidalgo, D; Murru, A; Saiz-Ruiz, J; Vieta, E | 1 |
Chang, CH; Chang, YC; Chen, YW; Cheng, YS; Chung, W; Tseng, PT; Wang, HY; Wu, CK | 1 |
Addington, J; Gallego, JA; John, M; Kane, JM; Lencz, T; Malhotra, AK; Robinson, DG; Tohen, M; Yu, J; Zhang, JP | 1 |
Addington, J; Bennett, N; Braga, RJ; Correll, CU; Gallego, JA; Greenberg, J; Hassoun, Y; John, M; Kane, JM; Kellner, CH; Lencz, T; Lopez, L; Malhotra, AK; Naraine, M; Petrides, G; Robinson, DG; Sevy, SM; Tohen, M; Zhang, JP | 1 |
Arango, C | 1 |
Addington, J; Burdick, KE; DeRosse, P; Gallego, JA; Goldberg, TE; Hassoun, Y; John, M; Kane, JM; Kellner, CH; Lencz, T; Malhotra, AK; Petrides, G; Robinson, DG; Tohen, M; Trampush, JW; Zhang, JP | 1 |
De Risio, L; Di Nicola, M; Fasano, A; Janiri, L; Martinotti, G; Pettorruso, M | 1 |
Ahn, J; Joe, S; Lim, J; Park, C; Park, J | 1 |
Chan, HY; Chen, WJ; Hsieh, MH; Hwang, TJ; Hwu, HG; Kuo, CH; Lin, CF; Liu, CC; Liu, CM; Lo, WM | 1 |
Prommer, E | 1 |
Aitchison, KJ; Heald, AH; Lodhi, RJ; Malik, A; Masand, S; McAllister, VD; O'Keane, V; Sherwood, RA; Shivakumar, K; Young, LC | 1 |
Aggarwal, A; Gopalakrishna, G; Lauriello, J | 1 |
Abadi, S; Joober, R; Lepage, M; Malla, A; Mustafa, S; Rho, A | 1 |
Bruhn, CH; Fink-Jensen, A; Jakobsen, KD; Nielsen, J; Pagsberg, AK | 1 |
Cocker, KE; Reese, TR; Thiel, DJ | 1 |
Alonso-Martín, C; Arias-Loste, MT; Crespo, J; Crespo-Facorro, B; Fábrega, E; Martínez-García, O; Morlán-Coarasa, MJ; Ortiz-García de la Foz, V; Romero-Gómez, M | 1 |
Du, Y; Jamal, HH; Pendergrass, JC; Risinger, R; Silverman, BL; Targum, SD | 1 |
Chen, YW; Tseng, PT | 1 |
Mahapatra, A; Sagar, R; Sharma, P | 1 |
Gallego, JA; Malhotra, AK; Rhindress, K; Robinson, DG; Szeszko, PR; Wellington, R | 1 |
Amado-Señaris, JA; Ayesa-Arriola, R; Correll, C; Crespo-Facorro, B; Labad, J; Ortiz-Garcia de la Foz, V; Pérez-Iglesias, R; Suarez-Pinilla, P; Teresa Garcia-Unzueta, M; Valdizan, EM | 1 |
Azorin, JM; Camus, V; Costentin, J; Crocq, MA; Daléry, J; Glikman, J; Krebs, MO; Limosin, F; Millet, B | 1 |
Sikich, L | 1 |
Breder, CD; Carson, WH; Marcus, R; McQuade, R; Porsteinsson, AP; Streim, JE; Swanink, R | 1 |
Tsai, AC | 1 |
Berman, RM; Breder, C; Campos, JA; Carson, WH; Kerselaers, W; L'italien, GJ; Marcus, RN; McQuade, RD; Newcomer, JW; Nys, M | 1 |
Gründer, G; Sheldrick, AJ | 1 |
Carlat, D | 1 |
Ibe, AI; Lee, JH; Makhzoumi, ZH; McLean, LP | 1 |
Chou, YH; Lin, WC | 1 |
Choi, JS; Jang, IJ; Kang, DH; Kim, E; Kwon, JS; Shin, SG; Yu, KS | 1 |
Azzoni, A; Raja, M | 1 |
Nakaya, M; Ohmori, K | 1 |
Coffey, BJ; Groff, K | 1 |
Madhusoodanan, S; Shah, P | 1 |
Ammerman, DK; Coley, KC; Fabian, TJ; Ganguli, R; Kim, E; Kim, MS; Saul, MI; Scipio, TM; Whitehead, R | 1 |
Baker, RA; Byerly, MJ; Eudicone, JM; Marcus, RN; Tran, QV; Whitehead, R | 1 |
Bledowski, J; Kahn, DA; Pandurangi, A; Trutia, A | 1 |
Denninger, JW; Dording, C; Fava, M; Hilliker, S; Homberger, C; Matthews, JD; Park, L; Rooney, K; Siefert, C; Sklarsky, K; van Nieuwenhuizen, AO | 1 |
Cho, SJ; Jang, JH; Kang, DH; Kim, YK; Kwon, JS; Yoo, SY | 1 |
Chang, CC; Chen, SH; Hsu, WY | 1 |
Kyomen, HH; Whitfield, TH | 1 |
Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Glick, ID; Janicak, PG; Marcus, RN; Marder, SR; McQuade, RD | 1 |
Assunção-Talbott, S; Eudicone, JM; Glick, ID; Mankoski, R; Marcus, RN; Tran, QV | 1 |
Bueno, JR; Campos, JA; Chaves, A; de Abreu, PB; de Matos E Souza, FG; de Oliveira, IR; de Sena, EP; E Silva, JA; Elkis, H; Gattaz, WF; Louzã, MR | 1 |
Adan-Manes, J; Garcia-Parajua, P | 1 |
Bashir, M; Keith, S; MacRae, A; Majjiga, C; Murphy, J; Shajahan, P; Taylor, M | 1 |
Coley, KC; Fabian, TJ; Lenze, EJ; Ruby, C; Scipio, TM | 1 |
Pae, CU | 1 |
Kumar, R; Sachdev, PS | 1 |
Kalapatapu, RK; Schimming, C | 1 |
Chung, S; Jeon, YW; Jeong, B; Jun, TY; Jung, HY; Kim, CE; Kim, CY; Kim, DH; Kwon, JS; Lee, JN; Lee, MS | 1 |
Dziuba, J; Keshavan, M; Lachover, L; Manji, S; Pizzuti, A; Rajarethinam, R | 1 |
Kalapatapu, RK | 1 |
Huang, YC; Lee, Y; Lin, PY | 1 |
Christodoulou, C; Douzenis, A; Gournellis, R; Lykouras, LP; Rizos, E | 1 |
Mace, S; Taylor, D | 1 |
Kashima, H; Kobayashi, H; Koshikawa, H; Mizuno, M; Morita, K; Takeshi, K; Yamazawa, R | 1 |
Chen, YJ; Hsueh, WC; Liao, KC; Lin, KH; Lin, YT; Lu, CL; Yen, MH | 1 |
Bat-Pitault, F; Delorme, R | 1 |
Assunção-Talbott, S; Carson, WH; Correll, CU; Goff, DC; Kane, JM; Kirkpatrick, B; Marder, SR; Pikalov, A; Sun, W; Vester-Blokland, E | 1 |
Leckband, SG; Meyer, JM; Strack, DK | 1 |
Assunção-Talbott, S; Barnes, TR; Buckley, P; Correll, CU; Eudicone, J; Kane, JM; McQuade, R; Pikalov, A; Sachs, G; Tran, QV | 1 |
McIntyre, RS | 1 |
Stip, E; Tourjman, V | 1 |
Chou, JC | 1 |
Audino, B; Curtis, J; Donohue, AM; Filymer, DM; Finkel, N; Josiassen, RC; Kacso, M; Shaughnessy, RA; Skuban, N | 1 |
Barth, KS; Garner, A; Phan, SV; Snarr, BS; VandenBerg, AM | 1 |
Manoj, P; Skopek, M | 1 |
Hwu, HG; Lai, MC; Liu, CC; Sheu, YH; Wu, SY | 1 |
Elsom, SJ; Gurvich, C; Kulkarni, J; McCauley-Elsom, K | 1 |
Chi, CH; Hsieh, PH; Hwang, KS; Lin, CE; Tzeng, NS | 1 |
Fleischhacker, WW; Hoertnagl, C; Hofer, A; Pfaffenberger, N | 1 |
Remington, G | 1 |
Kapur, S; Patel, MX; Sparshatt, A; Taylor, D | 1 |
Konstantakopoulos, G; Kouzoupis, AV; Mourikis, I; Oulis, P; Papageorgiou, SG | 1 |
Chou, YH; Wang, SJ; Wu, CL; Yang, KC | 1 |
Chen, CH; Chiu, YH; Lu, ML | 1 |
Claes, S; De Hert, M; Martens, GJ; Moons, T; Peuskens, J; Van Loo, KM; Van Schijndel, JE; van Winkel, R | 1 |
Correll, CU | 1 |
Gumus, S; Kamberyan, K; Saatcioglu, O; Yanik, M | 1 |
Bobo, WV; Crystal, S; Gerhard, T; Huang, C; Lieberman, JA; Olfson, M | 1 |
Kobayashi, T | 1 |
Alexander, J; Lecamwasam, DL | 1 |
Bang, L; Harris, TB; Mian, A; Muscal, E | 1 |
Hamer, RH; LaVange, LM; Lieberman, JA; McEvoy, JP; Nussbaum, AM; Perkins, DO; Ring, KD; Rosenheck, RA; Stroup, TS; Swartz, MS | 1 |
de Arce Cordón, R; Eding, E; Marques-Teixeira, J; Milanova, V; Rancans, E; Schreiner, A | 1 |
Bechdolf, A; Brüne, M; de Millas, W; Gaebel, W; Heinz, A; Janssen, B; Klosterkötter, J; Krüger-Özgürdal, S; Lambert, M; Lautenschlager, M; Maier, W; Michel, TM; Müller, H; Naber, D; Riedel, M; Schneider, F; Stützer, H; Wagner, M; Wobrock, T | 1 |
Weiden, PJ | 1 |
Babu, GN; Chandra, P; Kumar, R; Saddichha, S | 1 |
Ikeda, R; Katagiri, N; Mizumura, S; Mizuno, M; Nemoto, T; Shiraga, N; Tohgi, N; Tsujino, N; Yamaguchi, T | 1 |
Ishitobi, M; Kosaka, H; Murata, T; Oonuma, M; Takahashi, T; Wada, Y | 1 |
Brotzge, K; El-Mallakh, RS; Manshadi, M | 1 |
Grohmann, R; Holl, AK; Letmaier, M; Painold, A; Vergin, H | 1 |
Bobo, WV; Chen, Y; Jayathilake, K; Meltzer, HY; Tang, T; Watts, K | 1 |
Bou Khalil, R; Dahdah, P; Kahn, DA; Richa, S | 1 |
Chatziioannou, S; Filippopoulou, A; Lykouras, L; Peppa, M; Rizos, E; Tsigkaropoulou, E; Xelioti, I; Zompola, C | 1 |
Andrade, C; Chittaranjan, AC; Mendhekar, DN | 1 |
Hon, A | 1 |
Doey, T | 1 |
Mari, Jde J; Moreira, HC; Nunes, LV; Nunes, SO; Razzouk, D | 1 |
Nasti, JJ | 1 |
Chen, CK; Chou, MC; Chou, WJ; Huang, YS; Liang, HY; Tang, CS; Wang, LJ; Wu, YY; Yeh, CB | 1 |
Bradshaw, B; Henry, J; Macedo, LR; Marino, J | 1 |
Chen, CK; Hsiao, CC; Huang, YS; Ree, SC; Wang, LJ | 1 |
Adams, CE; Jones, H; Powney, MJ | 1 |
Arndt, S; Glorioso, DK; Golshan, S; Henry, R; Jeste, DV; Jin, H; Kraemer, HC; Mudaliar, S; Shih, PA | 1 |
Chien, YL; Hsieh, MH; Hwang, TJ; Hwu, HG; Liu, CC; Liu, CM | 1 |
Anttila, E; Lahti, A; Räsänen, P; Riala, K | 1 |
Higuchi, Y; Kawasaki, Y; Miyanishi, T; Seo, T; Sumiyoshi, T; Suzuki, M | 1 |
De Deyn, PP; Drenth, AF; Kremer, BP; Oude Voshaar, RC; Van Dam, D | 1 |
Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL | 1 |
Ali, M; Iwamoto, T; Kaplita, S; Marcus, R; Marder, SR; McQuade, RD; Safferman, AZ; Saha, A; Stock, E | 1 |
Ali, M; Carson, WH; Ingenito, G; Kujawa, MJ; Marder, SR; Potkin, SG; Saha, AR; Stock, E; Stringfellow, J | 1 |
Duggal, HS | 1 |
Argo, TR; Carnahan, RM; Perry, PJ | 1 |
Green, B | 1 |
Lieberman, JA | 1 |
Petty, F; Praveen, F; Ramaswamy, S; Sattar, SP; Vijay, D; William, M | 1 |
Crismon, ML; DeLeon, A; Patel, NC | 1 |
Mack, JE; Reeves, RR | 1 |
Perry, CM; Swainston Harrison, T | 1 |
Davids, E; Fischer, B; Gastpar, M | 1 |
Bowers, MB; Cooper, C; Lim, S; Pralea, C; Schnitt, J | 1 |
Bogunovic, O; Brenner, R; Gupta, S; Madhusoodanan, S; Reddy, H | 1 |
Finkel, S | 1 |
Katz, IR | 1 |
Cheney, EM; DeQuardo, JR; Sajbel, TA | 1 |
Bark, N; Citrome, L; Josiassen, R; Mallikaarjun, S; Salazar, DE | 1 |
Barzman, DH; Campbell, P; DelBello, MP; Delgado, SV; Fleck, DE; Gernert, B; Kowatch, RA; Pathak, S; Rappaport, K; Strakowski, SM | 1 |
Errico, JR; Yates, WR | 1 |
DeQuardo, JR | 1 |
Beard, L; Brown, ES; Garza, M; Jeffress, J; Liggin, JD | 1 |
Baldessarini, RJ; Centorrino, F; Cimbolli, P; Cincotta, SL; Fogarty, KV; Salvatore, P; Sani, G; Thompson, TA | 1 |
Ball, MP; Cates, ME; Hooper, ET; Skipwith, DF | 1 |
Breder, C; Carson, WH; De Deyn, P; Iwamoto, T; Jeste, DV; Kostic, D; Swanink, R | 1 |
Fricchione, GL; Huffman, JC | 1 |
Baldessarini, RJ; Grant, MJ | 1 |
Scholten, MR; Selten, JP | 1 |
Minervini, L; Romano, M; Ruffatti, A; Sonino, N | 1 |
Engelhardt, E; Laks, J; Marinho, V; Miotto, R | 1 |
Barnas, ME; Hussain, N; Petrides, G | 1 |
Howland, RH | 1 |
Folnegović-Smalc, V; Kozumplik, O; Mimica, N; Uzun, S | 1 |
Carson, WH; Citrome, L; Czobor, P; Hardy, S; Kostic, D; Marcus, R; McQuade, RD; Volavka, J | 1 |
Borba, CP; Cather, C; Daley, TB; Evins, AE; Freudenreich, O; Goff, DC; Henderson, DC; Kunkel, L; Louie, PM; Nguyen, DD | 1 |
Aderhold, V; Haasen, C; Lambert, M; Reimer, J | 1 |
Ballard, C; Waite, J | 1 |
Calliess, IT; Kropp, S; Sieberer, M; Ziegenbein, M | 1 |
Crandall, DT; Iwamoto, T; Kostic, D; Marcus, RN; McQuade, RD; Nyilas, M; Pans, M; Riera, LC; Stock, EG; Tandon, R | 1 |
Raja, M | 1 |
Arends, J; Slooff, CJ | 1 |
Beers, E; Loonen, AJ; Van Grootheest, AC | 1 |
Blashki, G; Keks, N | 1 |
Hara, C; Rocha, FL | 1 |
Clarke, LA; Kaushik, S; Lindenmayer, JP | 1 |
Andrade, C; Mendhekar, DN; Sunder, KR | 1 |
Ali, IM; Morris, HR; Wickremaratchi, M | 1 |
Alla, L; Sabaratnam, M; Shastri, M | 1 |
Andrezina, R; Carson, WH; Iwamoto, T; Josiassen, RC; Manos, G; Marcus, RN; Oren, DA; Stock, E | 1 |
Balhara, YP; Kayal, M; Varghese, ST | 1 |
Berman, RM; Carson, WH; Factor, SA; Friedman, JH; Goetz, CG; Marcus, RN; Ondo, WG; Wojcieszek, J | 1 |
Barlow, KB; Kapur, S; Natesan, S; Nobrega, JN; Reckless, GE | 1 |
De Oliveira, IR; Juruena, MF | 1 |
Chen, CH; Haw-Ming, L; Lin, CC; Shen, YC | 1 |
Arlien-Soborg, P; Kondziella, D | 1 |
Padala, PR; Petty, F; Wengel, SP | 1 |
Citrome, L; Jaffe, A; Levine, J | 1 |
Chan, HY; Chiang, SC; Hwang, TJ; Hwu, HG; Lin, SK; Lin, WW; Su, TP | 1 |
Auby, P; Marcus, RN; McQuade, RD; Oren, DA; Sack, DA; Tran-Johnson, TK | 1 |
Gründer, G; Hiemke, C; Kircher, T; Leube, D; Schlotterbeck, P | 1 |
Brunelle, J; Gouin, P; Guigueno, S; Tamion, F; Thibaut, F | 1 |
Alici-Evcimen, Y; Basil, B; Evcimen, H; Gorman, JM; Mania, I; Mathews, M | 1 |
Boulton, DW; Citrome, L; Macher, JP; Mallikaarjun, S; Salazar, DE | 1 |
Das, A; Desarkar, P; Nizamie, SH | 1 |
Bowers, MB; Lim, S | 1 |
Ahuja, N; Lloyd, AJ | 1 |
Allen, MH; Crandall, DT; Currier, GW; Daniel, DG; Manos, G; McQuade, R; Oren, D; Pikalov, AA; Zimbroff, DL | 1 |
Graff, A; Kapur, S; Mamo, D; Mizrahi, R; Romeyer, F; Shammi, CM | 1 |
Hurtig, HI; Weintraub, D | 1 |
Breder, CD; Forbes, A; Marcus, RN; McQuade, RD; Mintzer, JE; Swanink, R; Tune, LE | 1 |
Lu, JS; Pierre, JM | 1 |
Delgado, SV; Strawn, JR | 1 |
Aragona, M | 1 |
Amoretti, A; Di Lorenzo, R; Fiorini, F; Forghieri, M; Genedani, S; Rigatelli, M | 1 |
Faruqui, RA; Zaidi, SH | 1 |
Aydemir, MC; Goka, E; Kisa, C; Yalcin, DO | 1 |
Aitchison, KJ; McAllister, V; Mir, A; O'Keane, V; Shivakumar, K; Williamson, RJ | 1 |
Dale, R; Varkula, M | 1 |
De Hert, M; Hanssens, L; Peuskens, J; Scheen, A; Van Eyck, D; van Winkel, R; Wampers, M | 1 |
Englisch, S; Zink, M | 1 |
Stahl, SM | 2 |
Dorado, P; Llerena, A; López-Torres, E; Peñas-Lledó, E; Salomón, J; Vicario, F | 1 |
52 review(s) available for aripiprazole and Psychoses
Article | Year |
---|---|
Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review.
Topics: Antipsychotic Agents; Aripiprazole; Dementia; Humans; Olanzapine; Psychotic Disorders; Risperidone | 2021 |
Aripiprazole in young people with early psychosis: a systematic review and meta-analysis of weight gain.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Weight Gain | 2022 |
Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dementia; Humans; Network Meta-Analysis; Off-Label Use; Olanzapine; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Treatment Outcome | 2022 |
Pharmacological strategies for sexual recovery in men undergoing antipsychotic treatment.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Humans; Male; Psychotic Disorders; Risperidone; Sexual Dysfunction, Physiological | 2022 |
The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?
Topics: Antipsychotic Agents; Aripiprazole; Dopamine; Dopamine Agonists; Dopamine Antagonists; Humans; Polypharmacy; Psychotic Disorders; Quinolones; Thiophenes | 2022 |
Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: A systematic review and meta-analysis.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Hyperprolactinemia; Prolactin; Psychotic Disorders | 2020 |
Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Methamphetamine; Network Meta-Analysis; Olanzapine; Patient Dropouts; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia | 2021 |
Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis.
Topics: Antipsychotic Agents; Aripiprazole; Clopenthixol; Delayed-Action Preparations; Flupenthixol; Fluphenazine; Haloperidol; Humans; Injections, Intramuscular; Network Meta-Analysis; Olanzapine; Paliperidone Palmitate; Patient Acceptance of Health Care; Phenothiazines; Psychotic Disorders; Risperidone; Schizophrenia; Secondary Prevention | 2021 |
Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Drug Therapy, Combination; Humans; Meta-Analysis as Topic; Psychotic Disorders; Quality of Life; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology | 2017 |
[Aripiprazole as dopamine partial agonist model: Basic concepts and clinical impact].
Topics: Animals; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Psychotic Disorders; Schizophrenia | 2018 |
A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder.
Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Humans; Piperazines; Practice Guidelines as Topic; Psychoses, Substance-Induced; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology | 2013 |
Atypical antipsychotics for psychosis in adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Molindone; Olanzapine; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2013 |
Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Clozapine; Dibenzocycloheptenes; Drug Therapy, Combination; Heterocyclic Compounds, 4 or More Rings; Humans; Impulsive Behavior; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Polypharmacy; Psychotic Disorders; Quetiapine Fumarate; Receptors, Dopamine D2; Risperidone; Thiazoles; Violence | 2014 |
A safety evaluation of aripiprazole for treating schizophrenia during pregnancy and puerperium.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Postpartum Period; Pregnancy; Psychotic Disorders; Quinolones; Schizophrenia | 2014 |
Antipsychotic switching in schizoaffective disorder: A systematic review.
Topics: Antipsychotic Agents; Aripiprazole; Drug Substitution; Humans; Piperazines; Psychotic Disorders; Randomized Controlled Trials as Topic; Risperidone; Thiazoles | 2016 |
Atypical neuroleptic malignant syndrome in patients treated with aripiprazole and clozapine: a case-series study and short review.
Topics: Adult; Aripiprazole; Clozapine; Creatine Kinase; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Female; Fluoxetine; Hospitalization; Humans; Injections, Intramuscular; Male; Middle Aged; Neuroleptic Malignant Syndrome; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology | 2015 |
Aripiprazole.
Topics: Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Delirium; Humans; Psychotic Disorders | 2017 |
Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents.
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Injections, Intramuscular; Psychotic Disorders; Schizophrenia; United States | 2016 |
Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use.
Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Basal Ganglia Diseases; Behavior Therapy; Benzodiazepines; Cognitive Behavioral Therapy; Dementia; Emotions; Humans; Hypotension, Orthostatic; Metabolic Syndrome; Neuroleptic Malignant Syndrome; Olanzapine; Practice Guidelines as Topic; Psychotic Disorders; Quetiapine Fumarate; Risperidone | 2016 |
A Review of Differences in Clinical Characteristics between Tardive Syndrome Induced or Improved by Aripiprazole Treatment.
Topics: Antipsychotic Agents; Aripiprazole; Dystonia; Humans; Parkinson Disease, Secondary; Psychotic Disorders; Tardive Dyskinesia | 2016 |
[Present data and treatment schedule of aripiprazole in the treatment of schizophrenia].
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Drug Administration Schedule; Follow-Up Studies; Humans; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2008 |
Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain Diseases; Child; Chronic Disease; Clozapine; Comorbidity; Disease Progression; Humans; Magnetic Resonance Imaging; Olanzapine; Piperazines; Prognosis; Psychotic Disorders; Quinolones; Schizophrenia; Thiazoles; Treatment Failure | 2008 |
Management of psychosis in patients with Alzheimer's disease: focus on aripiprazole.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Humans; Hyperglycemia; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2008 |
The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Evidence-Based Medicine; Female; Haloperidol; Humans; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Recurrence; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult | 2009 |
Akathisia and second-generation antipsychotic drugs.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Isoxazoles; Olanzapine; Piperazines; Piperidines; Prevalence; Psychomotor Agitation; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk Factors; Risperidone; Sulpiride; Thiazoles | 2009 |
Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Piperazines; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Schizophrenia | 2009 |
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Haloperidol; Humans; Hypnotics and Sedatives; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2010 |
Aripiprazole in schizophrenia and schizoaffective disorder: A review.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Nausea; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Weight Gain; Young Adult | 2010 |
Mixed episodes with psychotic features.
Topics: Acute Disease; Adult; Affect; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Evidence-Based Medicine; Hospitalization; Humans; Male; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Treatment Outcome; Valproic Acid | 2009 |
Antipsychotics in pregnancy.
Topics: Abnormalities, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes, Gestational; Dibenzothiazepines; Female; Humans; Infant, Newborn; Olanzapine; Piperazines; Pregnancy; Pregnancy Complications; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles | 2010 |
A systematic review of aripiprazole--dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring.
Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Piperazines; Positron-Emission Tomography; Psychotic Disorders; Quinolones; Receptors, Dopamine; Treatment Outcome | 2010 |
Switching and combining antipsychotics.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Decision Making; Female; Humans; Olanzapine; Piperazines; Polypharmacy; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Weight Gain | 2010 |
Lycanthropy as a culture-bound syndrome: a case report and review of the literature.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Behavior Control; Citalopram; Cultural Characteristics; Culture; Delusions; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Ethnopsychology; Female; Humans; Lebanon; Middle Aged; Mythology; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2012 |
Aripiprazole in pediatric psychosis and bipolar disorder: a clinical review.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Humans; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia | 2012 |
Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Substitution; Drug Therapy, Combination; Erectile Dysfunction; Female; Humans; Hyperprolactinemia; Male; Piperazines; Psychotic Disorders; Purines; Quinolones; Schizophrenia; Schizophrenic Psychology; Sexual Dysfunction, Physiological; Sildenafil Citrate; Sulfones; Vasodilator Agents | 2012 |
Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).
Topics: Aggression; Antipsychotic Agents; Aripiprazole; Clopenthixol; Dystonia; Haloperidol; Humans; Lorazepam; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Sleep; Thiazoles | 2012 |
Aripiprazole in the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Meta-Analysis as Topic; Off-Label Use; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine; Serotonin 5-HT2 Receptor Antagonists | 2013 |
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology | 2003 |
Focus on aripiprazole.
Topics: Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Interactions; Humans; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia | 2004 |
Dopamine partial agonists: a new class of antipsychotic.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Dopamine; Dopamine Agonists; Humans; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Serotonin; Treatment Outcome | 2004 |
Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia | 2004 |
Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Humans; Metabolic Clearance Rate; Piperazines; Psychotic Disorders; Quinolones; Receptors, Neurotransmitter; Schizophrenia; Tissue Distribution; Treatment Outcome | 2004 |
[Aripiprazole: a new atypical antipsychotic drug].
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic | 2004 |
Pharmacology of antipsychotics in the elderly: a focus on atypicals.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Serotonin Antagonists; Thiazoles; Treatment Outcome; United States | 2004 |
Optimizing atypical antipsychotic treatment strategies in the elderly.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Controlled Clinical Trials as Topic; Dementia; Dibenzothiazepines; Humans; Olanzapine; Parkinson Disease; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Treatment Outcome | 2004 |
Aripiprazole: an overview of a novel antipsychotic.
Topics: Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Brain; Clinical Trials as Topic; Half-Life; Humans; Metabolic Clearance Rate; Piperazines; Psychotic Disorders; Quinolones; Receptors, Neurotransmitter; Treatment Outcome | 2005 |
Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Double-Blind Method; Female; Haloperidol; Hostility; Humans; Male; Middle Aged; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2005 |
The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
Topics: Aggression; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Humans; Mental Disorders; Olanzapine; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone | 2006 |
Treatment of psychosis: 30 years of progress.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Schizophrenia; Thiazoles | 2006 |
Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Cholinesterase Inhibitors; Clozapine; Controlled Clinical Trials as Topic; Dibenzothiazepines; Humans; Lewy Body Disease; Male; Parkinson Disease; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones | 2007 |
Combined antipsychotic treatment involving clozapine and aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Weight Loss | 2008 |
Aripiprazole. Abilitat, OPC 14597.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dopamine D2 Receptor Antagonists; Humans; Piperazines; Psychotic Disorders; Quinolones; Receptors, Dopamine D2 | 2002 |
72 trial(s) available for aripiprazole and Psychoses
Article | Year |
---|---|
Early Antipsychotic Nonresponse as a Predictor of Nonresponse and Nonremission in Adolescents With Psychosis Treated With Aripiprazole or Quetiapine: Results From the TEA Trial.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Double-Blind Method; Female; Humans; Male; Predictive Value of Tests; Psychotic Disorders; Quetiapine Fumarate; Treatment Outcome | 2022 |
Association between C-reactive protein levels and antipsychotic treatment during 12 months follow-up period after acute psychosis.
Topics: Antipsychotic Agents; Aripiprazole; C-Reactive Protein; Follow-Up Studies; Humans; Psychotic Disorders | 2022 |
Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Lipids; Metabolome; Psychoses, Substance-Induced; Psychotic Disorders; Risperidone | 2022 |
Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Prospective Studies; Psychotic Disorders; Risperidone; Treatment Outcome | 2022 |
Prevention of First-Episode Psychosis in People at Clinical High Risk: A Randomized Controlled, Multicentre Trial Comparing Cognitive-Behavioral Therapy and Clinical Management Plus Low-Dose Aripiprazole or Placebo (PREVENT).
Topics: Antipsychotic Agents; Aripiprazole; Cognitive Behavioral Therapy; Humans; Knowledge; Psychotic Disorders; Treatment Outcome | 2023 |
Early Stabilization of Weight Changes Following Treatment With Olanzapine, Risperidone, and Aripiprazole: A 12-Month Naturalistic Study of First Episode Psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Body Mass Index; Female; Humans; Male; Olanzapine; Prospective Studies; Psychotic Disorders; Risperidone; Time Factors; Weight Gain; Young Adult | 2019 |
Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Haloperidol; Humans; Male; Olanzapine; Outcome Assessment, Health Care; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Young Adult | 2020 |
Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Psychotic Disorders; Schizophrenia; Treatment Outcome | 2020 |
A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Energy Metabolism; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Piperazines; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Thiazoles; Time Factors; Weight Gain; Young Adult | 2020 |
Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Norway; Olanzapine; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Treatment Outcome; Weight Gain; Young Adult | 2020 |
Aripiprazole vs Risperidone for the acute-phase treatment of first-episode psychosis: A 6-week randomized, flexible-dose, open-label clinical trial.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Prospective Studies; Psychotic Disorders; Risperidone; Treatment Outcome | 2021 |
Different neurocognitive profiles of risperidone and aripiprazole in the FIRST episode of psychosis: A 3-year follow-up comparison.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cognition; Cognition Disorders; Cohort Studies; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Mental Status and Dementia Tests; Middle Aged; Psychotic Disorders; Risperidone; Time Factors; Young Adult | 2021 |
Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Humans; Outcome Assessment, Health Care; Psychotic Disorders; Schizophrenia | 2017 |
Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Haloperidol; Humans; Incidence; Male; Olanzapine; Piperazines; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Risk Factors; Risperidone; Schizophrenia; Thiazoles; Young Adult | 2017 |
Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Drug Therapy, Combination; Feasibility Studies; Female; Follow-Up Studies; Humans; Injections; Male; Middle Aged; Models, Biological; Psychotic Disorders; Schizophrenia | 2017 |
Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Delayed-Action Preparations; Denmark; Double-Blind Method; Female; Humans; Male; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Regression Analysis; Treatment Outcome; Weight Gain | 2017 |
Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Male; Outcome Assessment, Health Care; Psychotic Disorders; Schizophrenia | 2017 |
Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Dibenzothiazepines; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Thiazoles; Triglycerides; Young Adult | 2018 |
Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Delayed-Action Preparations; Electrocardiography; Female; Heart Rate; Humans; Male; Psychotic Disorders; Quetiapine Fumarate | 2018 |
Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis: Results From the DAAMSEL Clinical Trial.
Topics: Adult; Amenorrhea; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Drug Therapy, Combination; Female; Galactorrhea; Humans; Medication Adherence; Oligomenorrhea; Premenopause; Prolactin; Psychotic Disorders; Quality of Life | 2018 |
Comparison of the anti-inflammatory effect of aripiprazole and risperidone in 75 drug-naïve first episode psychosis individuals: A 3 months randomized study.
Topics: Adult; Anti-Inflammatory Agents; Antipsychotic Agents; Aripiprazole; Biomarkers; Cytokines; Female; Humans; Longitudinal Studies; Male; Psychotic Disorders; Risperidone; Treatment Outcome | 2018 |
Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Humans; Male; Outcome Assessment, Health Care; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Thiazoles; Young Adult | 2018 |
Serum Level Measurements Optimize Aripriprazole Treatment in Adolescent Patients.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Germany; Humans; Psychotic Disorders | 2019 |
Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Body Mass Index; Child; Delayed-Action Preparations; Denmark; Double-Blind Method; Female; Humans; Male; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Regression Analysis; Treatment Outcome; Weight Gain | 2019 |
Hummingbird Study: a study protocol for a multicentre exploratory trial to assess the acceptance and performance of a digital medicine system in adults with schizophrenia, schizoaffective disorder or first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Biosensing Techniques; Cloud Computing; Humans; Medical Informatics Applications; Medication Adherence; Mobile Applications; Multicenter Studies as Topic; Olanzapine; Pragmatic Clinical Trials as Topic; Psychiatry; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Tablets; United Kingdom | 2019 |
Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: a 12-week randomized, flexible-dose, open-label trial.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Humans; Male; Outcome Assessment, Health Care; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Retrospective Studies; Thiazoles; Time Factors; Young Adult | 2013 |
Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Female; Humans; Male; Patient Dropouts; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Thiazoles; Treatment Outcome; Young Adult | 2014 |
The advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Predictive Value of Tests; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Republic of Korea; Treatment Outcome; Young Adult | 2014 |
White matter changes associated with antipsychotic treatment in first-episode psychosis.
Topics: Anisotropy; Antipsychotic Agents; Aripiprazole; Brain; Diffusion Tensor Imaging; Double-Blind Method; Female; Follow-Up Studies; Humans; Lipoproteins, LDL; Longitudinal Studies; Male; Nerve Fibers, Myelinated; Occipital Lobe; Parietal Lobe; Piperazines; Psychotic Disorders; Quinolones; Risperidone; Young Adult | 2014 |
Aripiprazole plus topiramate in opioid-dependent patients with schizoaffective disorder: an 8-week, open-label, uncontrolled, preliminary study.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Diagnosis, Dual (Psychiatry); Drug Administration Schedule; Drug Therapy, Combination; Female; Fructose; Humans; Male; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Topiramate; Treatment Outcome; Young Adult | 2014 |
Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Dibenzothiazepines; Double-Blind Method; Female; Humans; Male; Patient Selection; Piperazines; Psychotic Disorders; Quality of Life; Quetiapine Fumarate; Quinolones; Sample Size; Schizophrenia | 2014 |
Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cholesterol; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Piperazines; Prolactin; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Sex Factors; Thiazoles; Weight Gain | 2014 |
Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Cerebral Cortex; Connectome; Corpus Striatum; Drug Monitoring; Episode of Care; Female; Humans; Magnetic Resonance Imaging; Male; Neural Pathways; Piperazines; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia; Treatment Outcome | 2015 |
A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Male; Outcome Assessment, Health Care; Psychotic Disorders; Risperidone; Schizophrenia; Young Adult | 2015 |
Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Female; Humans; Male; Outcome Assessment, Health Care; Psychotic Disorders; Remission Induction; Risperidone; Schizophrenia; Young Adult | 2015 |
Fast Versus Slow Strategy of Switching Patients With Schizophrenia to Aripiprazole From Other Antipsychotics.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Psychotic Disorders; Schizophrenia; Treatment Outcome | 2015 |
Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Incidence; Male; Metabolic Diseases; Middle Aged; Non-alcoholic Fatty Liver Disease; Piperazines; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Young Adult | 2016 |
Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia.
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Outcome Assessment, Health Care; Psychotic Disorders; Schizophrenia; Sex Factors; Young Adult | 2017 |
Hippocampal subregion volume changes associated with antipsychotic treatment in first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dentate Gyrus; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Hippocampus; Humans; Magnetic Resonance Imaging; Male; Psychotic Disorders; Risperidone; Young Adult | 2017 |
Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1year study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Cohort Studies; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Prolactin; Psychotic Disorders; Quetiapine Fumarate; Sex Characteristics; Thiazoles; Time Factors; Young Adult | 2017 |
A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Behavioral Symptoms; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Nursing Homes; Piperazines; Psychotic Disorders; Quinolones; United States | 2008 |
A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Obesity; Olanzapine; Overweight; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Triglycerides | 2008 |
Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; Piperazines; Polymorphism, Genetic; Prolactin; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Schizophrenia; Young Adult | 2008 |
Treatment of psychotic disorders with aripiprazole in the emergency psychiatric setting.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Diagnostic and Statistical Manual of Mental Disorders; Dibenzothiazepines; Drug Therapy, Combination; Emergency Services, Psychiatric; Female; Humans; Intensive Care Units; Male; Middle Aged; Piperazines; Psychiatric Department, Hospital; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Severity of Illness Index; Treatment Outcome | 2008 |
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia; Sex Factors; Substance Withdrawal Syndrome; Young Adult | 2009 |
Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Treatment Outcome | 2009 |
Aripiprazole prescribing patterns and side effects in elderly psychiatric inpatients.
Topics: Aged; Aged, 80 and over; Aging; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Inpatients; Male; Mental Disorders; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Retrospective Studies; Schizophrenia; Treatment Outcome | 2009 |
A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Dopamine Antagonists; Female; Humans; Male; Patient Dropouts; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Severity of Illness Index | 2009 |
Effects of aripiprazole on insight and subjective experience in individuals with an at-risk mental state.
Topics: Adolescent; Adult; Aripiprazole; Female; Follow-Up Studies; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Thinking; Treatment Outcome; Young Adult | 2009 |
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Diagnostic and Statistical Manual of Mental Disorders; Dibenzothiazepines; Double-Blind Method; Drug Therapy, Combination; Fatigue; Female; Headache; Humans; Male; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Severity of Illness Index; Sleep Initiation and Maintenance Disorders; Treatment Outcome | 2009 |
Early intervention with second-generation antipsychotics in first-episode psychosis: results of an 8-week naturalistic study.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Time Factors | 2010 |
[Efficacy of aripiprazole on patients with at-risk mental state and subjective well-being].
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Humans; Male; Medication Adherence; Personal Satisfaction; Piperazines; Psychotic Disorders; Quinolones; Risk; Young Adult | 2010 |
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Cholesterol; Cholesterol, LDL; Combined Modality Therapy; Dibenzothiazepines; Diet, Reducing; Drug Substitution; Exercise; Humans; Hypercholesterolemia; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk; Risperidone; Schizophrenia; Treatment Outcome; Triglycerides | 2011 |
Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Drug Delivery Systems; Female; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Schizophrenia; Secondary Prevention; Time Factors | 2012 |
Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosi
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind Method; Early Medical Intervention; Female; Humans; Male; Piperazines; Placebos; Psychotic Disorders; Quinolones; Treatment Outcome; Young Adult | 2011 |
Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Atherosclerosis; Bipolar Disorder; Cohort Studies; Diagnostic and Statistical Manual of Mental Disorders; Drug Monitoring; Dyslipidemias; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; North America; Patient Dropouts; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Schizophrenia; Severity of Illness Index; Thiazoles; Weight Loss | 2012 |
Effectiveness of aripiprazole in adolescents and young adults with schizophrenia spectrum disorders: comparison of first-episode to recurrent psychosis.
Topics: Adolescent; Adolescent Behavior; Adult; Aripiprazole; Child; Female; Humans; Male; Piperazines; Psychotic Disorders; Quality of Life; Quinolones; Recurrence; Schizophrenia; Schizophrenic Psychology | 2013 |
Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Metabolic Syndrome; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Therapeutic Equipoise; Triglycerides; United States | 2013 |
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Double-Blind Method; Drug Administration Schedule; Electroencephalography; Female; Haloperidol; Humans; Hyperprolactinemia; Long QT Syndrome; Male; Piperazines; Placebos; Prolactin; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2002 |
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Double-Blind Method; Female; Hospitalization; Humans; Male; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2003 |
Aripiprazole, a novel atypical antipsychotic drug.
Topics: Antipsychotic Agents; Aripiprazole; Forecasting; Humans; Piperazines; Psychotic Disorders; Quinolones | 2004 |
Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Comorbidity; Diagnosis, Dual (Psychiatry); Dopamine Agonists; Female; Humans; Male; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Substance-Related Disorders; Treatment Outcome | 2005 |
Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones | 2005 |
An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Clozapine; Community Mental Health Centers; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Triglycerides | 2006 |
A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA).
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Humans; Male; Piperazines; Primary Health Care; Prospective Studies; Psychiatry; Psychotic Disorders; Quinolones; Schizophrenia; Treatment Outcome | 2006 |
Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Anti-Dyskinesia Agents; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Blood Glucose; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Schizophrenia; Time Factors; Treatment Outcome; Withholding Treatment | 2006 |
Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; China; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Risperidone; Treatment Outcome | 2007 |
Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Schizophrenia; Treatment Outcome | 2007 |
Pharmacokinetics of aripiprazole and concomitant carbamazepine.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Carbamazepine; Drug Antagonism; Drug Therapy, Combination; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia | 2007 |
Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Schizophrenia | 2007 |
Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia; Basal Ganglia Diseases; Carbon Radioisotopes; Caudate Nucleus; Cerebral Cortex; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorine Radioisotopes; Humans; Male; Piperazines; Positron-Emission Tomography; Psychotic Disorders; Putamen; Pyridines; Pyrimidinones; Quinolones; Raclopride; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Treatment Outcome | 2007 |
Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Institutionalization; Male; Middle Aged; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Severity of Illness Index; Treatment Outcome | 2007 |
174 other study(ies) available for aripiprazole and Psychoses
Article | Year |
---|---|
Further evidence that antipsychotic medication does not prevent long-term psychosis in higher-risk individuals.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Prodromal Symptoms; Psychotic Disorders; Risk Factors | 2022 |
Amisulpride withdrawal akathisia responding to aripiprazole with propranolol in first-onset psychosis: a case report.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benztropine; Female; Humans; Hyperprolactinemia; Prolactin; Propranolol; Psychomotor Agitation; Psychotic Disorders; Young Adult | 2022 |
Case series on aripiprazole and dopamine supersensitivity psychosis.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine; Humans; Psychotic Disorders; Schizophrenia | 2022 |
Safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease-Results of a multicenter open trial.
Topics: Activities of Daily Living; Aripiprazole; Hallucinations; Humans; Parkinson Disease; Psychotic Disorders | 2022 |
Antipsychotic Exposure in Clinical High Risk of Psychosis: Empirical Insights From a Large Cohort Study.
Topics: Antipsychotic Agents; Aripiprazole; Cohort Studies; Female; Humans; Male; Psychotic Disorders; Risk Assessment; Risperidone | 2022 |
Lower Vitamin C Levels Are Associated With Less Improvement in Negative Symptoms in Initially Antipsychotic-Naïve Patients With First-Episode Psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Ascorbic Acid; Female; Humans; Psychotic Disorders; Schizophrenia; Young Adult | 2022 |
The plasma level of complement component 4A decreases with aripiprazole treatment in patients with early psychosis.
Topics: Aripiprazole; Complement C4a; Complement C4b; Enzyme-Linked Immunosorbent Assay; Humans; Psychotic Disorders | 2022 |
Combination therapy of modified electroconvulsive therapy and long-acting injectable aripiprazole for dopamine supersensitivity psychosis: a case report.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine; Electroconvulsive Therapy; Humans; Male; Psychotic Disorders | 2022 |
Visualizing classification of drugs used in psychotic disorders: A 'subway map' representing mechanisms, established classes and informal categories.
Topics: Antipsychotic Agents; Aripiprazole; Butyrophenones; Chlorpromazine; Dopamine; Dopamine Agonists; Histamine; Humans; Psychotic Disorders; Railroads; Receptors, Dopamine D2; Systematic Reviews as Topic | 2022 |
Acute Onset Psychosis With Mystical Delusions in a Young Male Patient Following Discontinuation of Corticosteroid Therapy: A Case Report.
Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Delusions; Haloperidol; Humans; Male; Psychotic Disorders | 2022 |
Weight changes in people with early psychosis treated with oral or long-acting injectable aripiprazole.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Injections; Psychotic Disorders; Schizophrenia | 2023 |
Polish Psychiatric Association diagnostic and therapeutic management guidelines for patients with early-onset schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Humans; Poland; Psychotic Disorders; Schizophrenia | 2022 |
Problem gambling among people with first-episode psychosis: protocol for a prospective multicenter cohort study.
Topics: Antipsychotic Agents; Aripiprazole; Gambling; Humans; Multicenter Studies as Topic; Prospective Studies; Psychotic Disorders; Young Adult | 2023 |
Dopaminergic and glutamatergic models of psychosis show differential sensitivity to aripiprazole and a novel experimental compound modulating D
Topics: Amphetamine; Animals; Antipsychotic Agents; Aripiprazole; Dizocilpine Maleate; Dopamine; Dose-Response Relationship, Drug; Psychotic Disorders; Quinolones; Rats; Receptors, Serotonin | 2023 |
Can brexpiprazole be switched safely in patients with schizophrenia and dopamine supersensitivity psychosis? A retrospective analysis in a real-world clinical practice.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine; Dopamine Agonists; Humans; Psychotic Disorders; Retrospective Studies; Schizophrenia | 2023 |
Program Evaluation to Aid Choice of Aripiprazole or Risperidone for Hospitalized Adolescents with Cannabis Use Disorder and Psychosis.
Topics: Adolescent; Adolescent, Hospitalized; Antipsychotic Agents; Aripiprazole; Humans; Marijuana Abuse; Program Evaluation; Psychotic Disorders; Retrospective Studies; Risperidone; Substance-Related Disorders | 2023 |
Predictors of hospitalisation and recovery following full antipsychotic discontinuation in first episode psychosis. A naturalistic retrospective cohort study.
Topics: Antipsychotic Agents; Aripiprazole; Hospitalization; Humans; Olanzapine; Psychotic Disorders; Retrospective Studies | 2023 |
Treatment of first-episode psychosis in patients with autism-spectrum disorder and intellectual deficiency
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Delusions; Dystonia; Female; Hallucinations; Humans; Hypnotics and Sedatives; Intellectual Disability; Lorazepam; Loxapine; Olanzapine; Paranoid Disorders; Psychotic Disorders; Quetiapine Fumarate; Tourette Syndrome | 2019 |
Aripiprazole for the Management of Antipsychotic-Induced Hyperprolactinemia A Retrospective Case Series.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Middle Aged; Prolactin; Psychotic Disorders; Retrospective Studies; Schizophrenia | 2020 |
Efficacy of Low-Dose Aripiprazole for Treatment of Psychotic Symptoms in a Patient with 22q11.2 Deletion Syndrome.
Topics: Adolescent; Aripiprazole; Child; DiGeorge Syndrome; Hallucinations; Humans; Male; Psychotic Disorders; Schizophrenia | 2020 |
Weight gain and metabolic screening in young people with early psychosis on long acting injectable antipsychotic medication (aripiprazole vs paliperidone).
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Paliperidone Palmitate; Psychotic Disorders; Schizophrenia; Weight Gain | 2021 |
Problem Gambling Associated with Aripiprazole: A Nested Case-Control Study in a First-Episode Psychosis Program.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Behavior Rating Scale; Canada; Case-Control Studies; Causality; Female; Gambling; Humans; Male; Personality Assessment; Psychopathology; Psychotic Disorders; Risk Adjustment; Risk Assessment; Risk Factors | 2021 |
New-onset psychosis: A case report of brief psychosis related to COVID-19 infection.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Aripiprazole; COVID-19; Diazepam; Humans; Male; Psychotic Disorders; SARS-CoV-2; Treatment Outcome | 2021 |
Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report.
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Drug Administration Schedule; Humans; Injections; Male; Middle Aged; Pharmacogenetics; Psychotic Disorders; Schizophrenia | 2017 |
Antipsychotic treatment of children and adolescents is a double-edged sword.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Double-Blind Method; Humans; Psychotic Disorders; Quetiapine Fumarate | 2017 |
Aripiprazole Improves Psychotic, Cognitive, and Motor Symptoms in a Patient With Lewy Body Dementia.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Cognitive Dysfunction; Humans; Lewy Body Disease; Male; Psychotic Disorders; Tremor | 2017 |
Antipsychotic therapy amongst Cytochrome P450 2D6 poor metabolizers in the clinical practice: A case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Humans; Male; Psychotic Disorders | 2017 |
[Aripiprazole-Induced Hyperhidrosis: Two Case Reports].
Topics: Administration, Oral; Adult; Antidepressive Agents, Tricyclic; Aripiprazole; Diagnosis, Differential; Female; Humans; Hyperhidrosis; Personality Disorders; Psychotic Disorders | 2017 |
Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia: a 24-week follow-up study.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Cohort Studies; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Psychotic Disorders; Schizophrenia; Taiwan; Tardive Dyskinesia | 2018 |
The incidence, psychiatric co-morbidity and pharmacological treatment of severe mental disorders in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Comorbidity; Depressive Disorder, Major; Female; Humans; Incidence; Infant; Male; Mental Disorders; Norway; Olanzapine; Prevalence; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia | 2018 |
Long-Acting Injectable Atypical Antipsychotic Use in Adolescents: An Observational Study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Child; Delayed-Action Preparations; Female; Hospitalization; Humans; Inpatients; Male; Off-Label Use; Paliperidone Palmitate; Psychiatric Status Rating Scales; Psychotic Disorders; Retrospective Studies; Risperidone; Treatment Outcome | 2018 |
Two-year effectiveness of risperidone and aripiprazole in the maintenance treatment of patients with recent-onset or chronic schizophrenia and related psychotic disorders: a retrospective multicenter study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Hospitals, Psychiatric; Humans; Middle Aged; Psychotic Disorders; Retrospective Studies; Risperidone; Schizophrenia; Survival Analysis; Young Adult | 2018 |
Can a digital medicine system improve adherence to antipsychotic treatment?
Topics: Antipsychotic Agents; Aripiprazole; Evidence-Based Practice; Humans; Medication Adherence; Psychotic Disorders; Telemedicine; United States; United States Food and Drug Administration | 2018 |
Psychosis, creativity and recovery: exploring the relationship in a patient.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Creativity; Female; Humans; Medication Adherence; Paranoid Behavior; Psychotic Disorders; Recurrence; Writing | 2018 |
Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetes, Gestational; Female; Humans; Olanzapine; Piperazines; Pregnancy; Pregnancy Complications; Psychotic Disorders; Quetiapine Fumarate; Risk Factors; Risperidone; Thiazoles; Young Adult | 2018 |
Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Paliperidone Palmitate; Psychotic Disorders; Schizophrenia; Young Adult | 2018 |
[Evaluation of verbal inhibitory control with the Stroop Test in early episodes of psychosis with the experience of traumatic events in infancy].
Topics: Adolescent; Age Factors; Aripiprazole; Child; Child, Preschool; Executive Function; Female; Humans; Infant; Inhibition, Psychological; Male; Prefrontal Cortex; Psychotic Disorders; Risperidone; Stress Disorders, Traumatic; Stroop Test; Surveys and Questionnaires; Verbal Behavior | 2018 |
Can low-dose aripiprazole reverse some of the adverse effects from a long-acting injectable?
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Hyperprolactinemia; Injections; Psychotic Disorders | 2019 |
Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Cerebral Cortex; Clozapine; Depressive Disorder, Major; Electroencephalography; Female; Humans; Male; Mental Disorders; Middle Aged; Olanzapine; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Young Adult | 2018 |
No Differences in Weight Gain Between Risperidone and Aripiprazole in Children and Adolescents After 12 Months.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Body Mass Index; Child; Female; Humans; Male; Netherlands; Psychotic Disorders; Retrospective Studies; Risperidone; Time Factors; Weight Gain | 2019 |
Impact of the CYP2D6 phenotype on hyperprolactinemia development as an adverse event of treatment with atypical antipsychotic agents in pediatric patients.
Topics: Adolescent; Alleles; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Cytochrome P-450 CYP2D6; Female; Humans; Hyperprolactinemia; Male; Phenotype; Prospective Studies; Psychotic Disorders; Risperidone; Schizophrenia; Young Adult | 2019 |
Commentary: Aripiprazole: The Second Wave of the Second-generation Antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dopamine Agents; History, 21st Century; Humans; Mental Disorders; Psychotic Disorders; Schizophrenia | 2019 |
Editorial: Making Use of What We Know: Medical Decision-Making and Antipsychotics.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Child; Clinical Decision-Making; Diabetes Mellitus, Type 2; Humans; Psychotic Disorders; Quetiapine Fumarate | 2019 |
Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Female; Genotype; Humans; Male; Middle Aged; Norway; Pharmacogenomic Variants; Psychotic Disorders; Retrospective Studies; Risperidone; Treatment Failure; Young Adult | 2019 |
Aripiprazole Combined with Lamotrigine in the Treatment of a Treatment-Resistant Schizophrenic Patient with Tardive Dyskinesia and Supersensitivity Psychosis.
Topics: Antipsychotic Agents; Aripiprazole; Drug Resistance; Drug Therapy, Combination; Humans; Lamotrigine; Male; Middle Aged; Psychotic Disorders; Schizophrenia; Tardive Dyskinesia; Treatment Outcome | 2019 |
Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's disease.
Topics: Adult; Aggression; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Huntington Disease; Male; Morpholines; Piperazines; Psychotic Disorders; Quinolones; Reboxetine; Treatment Outcome | 2013 |
Aripiprazole treatment for choreoathetoid and psychotic symptoms of Huntington's disease.
Topics: Antipsychotic Agents; Aripiprazole; Athetosis; Chorea; Humans; Huntington Disease; Piperazines; Psychotic Disorders; Quinolones | 2013 |
Neurocognitive effects of aripiprazole in adolescents and young adults with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brief Psychiatric Rating Scale; Child; Cognition; Female; Humans; Male; Neuropsychological Tests; Piperazines; Prospective Studies; Psychotic Disorders; Quality of Life; Quinolones; Schizophrenia; Taiwan; Treatment Outcome; Young Adult | 2014 |
Ceftriaxone and infection in first episode adolescent psychosis.
Topics: Adolescent; Anti-Bacterial Agents; Aripiprazole; Bacterial Infections; Ceftriaxone; Humans; Male; Piperazines; Psychotic Disorders; Quinolones | 2013 |
[Emergency psychopharmacotherapy in Hungary -- preliminary data].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clopenthixol; Droperidol; Drug Prescriptions; Drug Therapy, Combination; Emergency Treatment; Female; Haloperidol; Humans; Hungary; Male; Middle Aged; Olanzapine; Piperazines; Practice Patterns, Physicians'; Promethazine; Psychiatry; Psychomotor Agitation; Psychotic Disorders; Quinolones; Surveys and Questionnaires | 2014 |
Worsening of psychosis with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Psychotic Disorders; Quinolones | 2014 |
Effects of antipsychotic drugs on insight in schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Awareness; Benzodiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2014 |
[Antipsychotics -- do they exist?].
Topics: Adaptation, Psychological; Affect; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Corpus Striatum; Depressive Disorder, Major; Dopamine; Dopamine Agents; Humans; Obsessive-Compulsive Disorder; Off-Label Use; Piperazines; Psychotic Disorders; Quinolones; Risperidone; Stress, Psychological; Thinking | 2014 |
Hiccup with aripiprazole plus benzodiazepines resolving with pregabalin and/or benzodiazepine switch/discontinuation: four case reports.
Topics: Adolescent; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Benzodiazepines; Calcium Channel Blockers; Hiccup; Humans; Male; Marijuana Abuse; Pregabalin; Psychoses, Substance-Induced; Psychotic Disorders; Substance-Related Disorders; Young Adult | 2015 |
Aripiprazole-Induced Hypoprolactinemia in an Adult Male with First-Episode Psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Prolactin; Psychotic Disorders | 2016 |
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.
Topics: Adolescent; Affective Disorders, Psychotic; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Benzodiazepines; Blood Glucose; Child; Child, Preschool; Cohort Studies; Conduct Disorder; Databases, Factual; Depressive Disorder; Diabetes Mellitus; Female; Glycated Hemoglobin; Guideline Adherence; Humans; Hyperkinesis; Male; Mass Screening; Mental Disorders; Olanzapine; Piperazines; Practice Guidelines as Topic; Practice Patterns, Physicians'; Psychotic Disorders; Quetiapine Fumarate; Retrospective Studies; Risperidone; Thiazoles | 2015 |
Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Genetic Loci; Humans; Male; Outcome Assessment, Health Care; Polymorphism, Single Nucleotide; Psychotic Disorders; Randomized Controlled Trials as Topic; Receptors, Dopamine D2; Risk; Risperidone; Schizophrenia; Young Adult | 2015 |
First-Episode Psychosis Research: Time to Move Forward (by Looking Backwards).
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Outcome Assessment, Health Care; Psychotic Disorders; Risperidone; Schizophrenia | 2015 |
Management of aripiprazole-induced tardive Pisa syndrome: a case report and literature review.
Topics: Adult; Algorithms; Antipsychotic Agents; Aripiprazole; Case Management; Female; Humans; Movement Disorders; Psychotic Disorders; Syndrome; Treatment Outcome | 2016 |
Remission of irreversible aripiprazole-induced tardive dystonia with clozapine: a case report.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clozapine; Dyskinesia, Drug-Induced; Humans; Male; Movement Disorders; Neurologic Examination; Psychotic Disorders; Treatment Outcome; Young Adult | 2015 |
Changes in biomarkers of bone turnover in an aripiprazole add-on or switching study.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Biomarkers; Bipolar Disorder; Bone Remodeling; Estrogens; Female; Follow-Up Studies; Humans; Male; Middle Aged; PAX5 Transcription Factor; Prolactin; Prospective Studies; Psychotic Disorders; Schizophrenia; Sensitivity and Specificity; Testosterone; Young Adult | 2016 |
Therapeutic effectiveness and tolerability of aripiprazole as initial choice of treatment in first episode psychosis in an early intervention service: A one-year outcome study.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Energy Metabolism; Female; Follow-Up Studies; Humans; Male; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Treatment Outcome; Weight Gain; Young Adult | 2016 |
Neurological, Metabolic, and Psychiatric Adverse Events in Children and Adolescents Treated With Aripiprazole.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Child; Child, Preschool; Databases, Factual; Denmark; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Neurodevelopmental Disorders; Obsessive-Compulsive Disorder; Psychotic Disorders; Schizophrenia; Tourette Syndrome | 2016 |
Aripiprazole induced Impulse Control Disorders: Where do we stand?
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Disruptive, Impulse Control, and Conduct Disorders; Female; Humans; Male; Middle Aged; Psychotic Disorders; Schizophrenia; Young Adult | 2016 |
Significance of findings in aripiprazole for treatment of psychoses in Alzheimer dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Humans; Patient Dropouts; Piperazines; Psychotic Disorders; Quinolones; Research Design; Treatment Outcome | 2008 |
Aripiprazole reduces serum prolactin in a woman with prolactinoma and acute psychosis.
Topics: Adult; Aripiprazole; Female; Humans; Piperazines; Pituitary Neoplasms; Prolactin; Prolactinoma; Psychotic Disorders; Quinolones | 2008 |
Apparent commercial bias in supplement.
Topics: Antipsychotic Agents; Aripiprazole; Bias; Commerce; Health Status; Humans; Patient Satisfaction; Piperazines; Psychopharmacology; Psychotic Disorders; Quinolones | 2008 |
Diabetic ketoacidosis associated with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Diabetic Ketoacidosis; Fluid Therapy; Humans; Hypoglycemic Agents; Insulin; Male; Piperazines; Psychotic Disorders; Quinolones | 2008 |
Aripiprazole effects on psychosis and chorea in a patient with Huntington's disease.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Huntington Disease; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones | 2008 |
Aripiprazole treatment for depression in schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depression; Female; Humans; Piperazines; Psychotic Disorders; Quinolones | 2008 |
Psychosis or atypical neuroleptic malignant syndrome in an adolescent?
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Diagnosis, Differential; Humans; Male; Neuroleptic Malignant Syndrome; Piperazines; Psychotic Disorders; Quinolones | 2008 |
Predictors of aripiprazole treatment continuation in hospitalized patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Child, Preschool; Cohort Studies; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Patient Discharge; Piperazines; Psychotic Disorders; Quinolones; Retrospective Studies; Treatment Outcome | 2008 |
Neuroleptic rechallenge with aripiprazole in a patient with previously documented neuroleptic malignant syndrome.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Creatine Kinase; Documentation; Female; Humans; Neuroleptic Malignant Syndrome; Piperazines; Psychotic Disorders; Quinolones | 2008 |
An open study of aripiprazole and escitalopram for psychotic major depressive disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Citalopram; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Selective Serotonin Reuptake Inhibitors | 2009 |
Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Mass Index; Body Weight; Female; Humans; Korea; Male; Middle Aged; Piperazines; Prolactin; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Suicide; Young Adult | 2009 |
Supersensitivity psychosis after tapering aripiprazole: a case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Fear; Hallucinations; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenic Psychology | 2009 |
Psychosis in the elderly.
Topics: Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Comorbidity; Cyclohexanols; Delirium; Depressive Disorder, Major; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Humans; Memantine; Nootropic Agents; Piperazines; Psychotherapy; Psychotic Disorders; Quinolones; Risk Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Female; Haloperidol; Humans; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Aripiprazole in combination with other antipsychotic drugs may worsen psychosis.
Topics: Amisulpride; Anti-Dyskinesia Agents; Antipsychotic Agents; Aripiprazole; Biperiden; Dopamine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia, Paranoid; Schizophrenic Psychology; Sulpiride; Young Adult | 2009 |
Comparing the effectiveness of aripiprazole and quetiapine in schizophrenia and related psychoses: a naturalistic, retrospective chart review study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Drug Administration Schedule; Female; Humans; Male; Medical Records Systems, Computerized; Mental Health Services; Patient Dropouts; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Retrospective Studies; Schizophrenia; Severity of Illness Index | 2009 |
Supersensitivity psychosis and aripiprazole tapering.
Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Humans; Piperazines; Psychotic Disorders; Quinolones | 2009 |
Update on neuropsychiatric symptoms of dementia: antipsychotic use.
Topics: Aged; Aggression; Antipsychotic Agents; Aripiprazole; Dementia; Geriatric Psychiatry; Humans; Piperazines; Psychotic Disorders; Quinolones; Risperidone; Severity of Illness Index | 2009 |
Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Fluphenazine; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Neurologic Examination; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia | 2009 |
Aripiprazole treatment of psychosis in a child with posterior fossa retrocerebellar arachnoid cyst.
Topics: Antipsychotic Agents; Arachnoid Cysts; Aripiprazole; Child; Cranial Fossa, Posterior; Female; Humans; Piperazines; Psychotic Disorders; Quinolones; Radiography | 2009 |
Reversible Pisa syndrome associated with switching from haloperidol to aripiprazole during lithium treatment.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Chloroquinolinols; Dystonia; Female; Humans; Lithium Compounds; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Spasm | 2009 |
Tardive dyskinesia in a patient treated with quetiapine.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dibenzothiazepines; Dyskinesia, Drug-Induced; Female; Humans; Middle Aged; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Sulpiride; Thiazoles | 2009 |
Serious generalized tonic-clonic seizures induced by aripiprazole.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Humans; Male; Phenytoin; Piperazines; Psychotic Disorders; Quinolones; Seizures | 2010 |
Aripiprazole and hypertension in adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Calcium Channel Blockers; Female; Humans; Hypertension; Nifedipine; Piperazines; Psychotic Disorders; Quinolones; Severity of Illness Index | 2009 |
Antipsychotic prescribing practices following withdrawal of concomitant carbamazepine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Carbamazepine; Cytochrome P-450 Enzyme System; Dibenzothiazepines; Drug Interactions; Drug Therapy, Combination; Enzyme Induction; Female; Humans; Male; Medical Audit; Middle Aged; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risk Factors; Risperidone | 2009 |
The role of aripiprazole in Canada: A review of clinical and drug discontinuation data. Foreword.
Topics: Antipsychotic Agents; Aripiprazole; Canada; Clinical Trials as Topic; Comorbidity; Drug Utilization; Drug Utilization Review; Humans; Metabolic Diseases; Mood Disorders; Piperazines; Psychotic Disorders; Quinolones; Risk Factors | 2010 |
Symptomatic bradycardia with oral aripiprazole and oral ziprasidone.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Bradycardia; Delusions; Electrocardiography; Female; Humans; Lithium Carbonate; Piperazines; Psychotic Disorders; Quinolones; Thiazoles | 2010 |
Hyperprolactinaemia during treatment with paliperidone.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Galactorrhea; Humans; Hyperprolactinemia; Isoxazoles; Middle Aged; Paliperidone Palmitate; Patient Compliance; Piperazines; Prolactin; Psychotic Disorders; Pyrimidines; Quetiapine Fumarate; Quinolones; Recurrence; Schizophrenia, Paranoid; Young Adult | 2010 |
Rapid response to antipsychotic treatment on psychotic prodrome: implications from a case series.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Treatment Outcome | 2010 |
Treatment of schizophreniform disorder by aripiprazole in a female adolescent with 22q11.2 deletion syndrome.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; DiGeorge Syndrome; Female; Humans; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2010 |
Aripiprazole add-on treatment in a patient with schizoaffective disorder: neurocognitive outcomes.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Drug Therapy, Combination; Humans; Male; Memory Disorders; Olanzapine; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2010 |
Antipsychotic dosing: still a work in progress.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Drug Administration Schedule; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Receptors, Dopamine D2; Severity of Illness Index | 2010 |
Aripiprazole in the treatment of olanzapine-resistant psychotic and motor symptoms of Huntington's disease.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Huntington Disease; Male; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Treatment Outcome | 2010 |
Aripiprazole can treat psychotic features but not motor symptoms of Parkinson's disease: evidence from a SPECT study.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Middle Aged; Parkinson Disease; Piperazines; Protein Binding; Psychotic Disorders; Quinolones; Tomography, Emission-Computed, Single-Photon | 2011 |
Worsening psychosis after adding aripiprazole to clozapine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Synergism; Humans; Male; Piperazines; Psychotic Disorders; Quinolones | 2011 |
Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs.
Topics: Adult; Age Factors; Alleles; Amisulpride; Anthropometry; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Composition; Body Mass Index; CLOCK Proteins; Clozapine; Dibenzothiazepines; Drug Therapy, Combination; Female; Genetic Association Studies; Genetic Carrier Screening; Genotype; Humans; Long-Term Care; Male; Middle Aged; Mutation, Missense; Olanzapine; Period Circadian Proteins; Piperazines; Polymorphism, Single Nucleotide; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Receptor, Melanocortin, Type 3; Receptors, Glucocorticoid; Receptors, Leptin; Risperidone; Schizophrenia; Sex Factors; Sulpiride; Syndecan-3 | 2011 |
Efficacy of high-dose aripiprazole for treatment-resistant schizoaffective disorder: a case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Labeling; Drug Resistance; Female; Humans; Off-Label Use; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2010 |
Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Dibenzothiazepines; Female; Hospitalization; Hospitals, Psychiatric; Humans; Male; Medication Adherence; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2012 |
Aripiprazole associated hyponatraemia.
Topics: Aripiprazole; Female; Humans; Hyponatremia; Middle Aged; Piperazines; Psychotic Disorders; Quinolones | 2011 |
Use of aripiprazole in adolescents with a history of lupus-associated psychosis and refractory psychiatric manifestations.
Topics: Adolescent; Adrenal Cortex Hormones; Antipsychotic Agents; Aripiprazole; Dyslipidemias; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Lupus Vasculitis, Central Nervous System; Neuropsychological Tests; Piperazines; Psychotic Disorders; Quinolones; Remission Induction; Treatment Outcome; Weight Gain | 2011 |
Switching antipsychotic medications: not enough, too often, or just right?
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Drug Substitution; Humans; Hypercholesterolemia; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia | 2011 |
Aripiprazole associated with acute dystonia, akathisia, and parkinsonism in a single patient.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Depression; Dystonia; Female; Fluoxetine; Humans; Parkinsonian Disorders; Piperazines; Psychotic Disorders; Quinolones | 2012 |
Cerebral blood flow changes in very-late-onset schizophrenia-like psychosis with catatonia before and after successful treatment.
Topics: Antipsychotic Agents; Aripiprazole; Brain; Brain Mapping; Catatonia; Cerebrovascular Circulation; Female; Haloperidol; Humans; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2011 |
Aripiprazole monotherapy in the treatment of vascular parkinsonism.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Parkinson Disease, Secondary; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2011 |
Intermittent aripiprazole for schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Retrospective Studies; Schizophrenia | 2012 |
Severe psychotic exacerbation during combined treatment with aripiprazole/haloperidol after prior treatment with risperidone.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Combinations; Drug Interactions; Female; Haloperidol; Humans; Piperazines; Psychoses, Substance-Induced; Psychotic Disorders; Quinolones; Recurrence; Risperidone | 2012 |
Hypogonadism due to hyperprolactinemia and subsequent first episode of psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cabergoline; Ergolines; Humans; Hyperprolactinemia; Hypogonadism; Male; Obesity, Morbid; Piperazines; Pituitary Neoplasms; Prolactin; Prolactinoma; Psychotic Disorders; Quinolones; Schizophrenia | 2012 |
Emergence of psychotic symptoms during Internet withdrawal.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Behavior, Addictive; Humans; Internet; Male; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2012 |
Factors influencing the adherence of antipsychotic medication (Aripiprazole) in first-episode psychosis: findings from a grounded theory study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Data Collection; Disability Evaluation; England; Female; Health Status; Humans; Interview, Psychological; Male; Medication Adherence; Nursing Theory; Patient Participation; Piperazines; Psychotic Disorders; Quality of Life; Quinolones; Young Adult | 2012 |
Is there a role for loading dose regimes in aripiprazole therapy?
Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Psychotic Disorders; Quinolones | 2012 |
Graves' hyperthyroidism-induced psychosis treated with aripiprazole--a case report.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Graves Disease; Humans; Middle Aged; Piperazines; Psychotic Disorders; Quinolones | 2013 |
Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
Topics: Adiponectin; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Female; Humans; Lipids; Male; Middle Aged; Obesity; Olanzapine; Piperazines; Prospective Studies; Psychotic Disorders; Quinolones; Weight Gain | 2013 |
Aripiprazole for drug-naive or antipsychotic-short-exposure subjects with ultra-high risk state and first-episode psychosis: an open-label study.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Chi-Square Distribution; Drug Administration Schedule; Female; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2013 |
Aripiprazole-related severe neuroleptic malignant syndrome with deep coma and organic brain changes in an antipsychotic-naive adolescent boy.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Brain; Coma; Diagnosis, Differential; Humans; Male; Neuroleptic Malignant Syndrome; Piperazines; Predictive Value of Tests; Psychotic Disorders; Quinolones; Treatment Outcome | 2013 |
Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Electroencephalography; Evoked Potentials; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Young Adult | 2013 |
Aripiprazole-induced improvement in tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Chronic Disease; Dyskinesia, Drug-Induced; Female; Humans; Piperazines; Psychotic Disorders; Quinolones; Severity of Illness Index | 2003 |
Aripiprazole possibly worsens psychosis.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Receptors, Dopamine D2 | 2004 |
Worsening schizoaffective disorder with aripiprazole.
Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Humans; Male; Middle Aged; Piperazines; Psychoses, Substance-Induced; Psychotic Disorders; Quinolones | 2004 |
Possible increased efficacy of low-dose clozapine when combined with aripiprazole.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia, Paranoid; Treatment Outcome | 2004 |
Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Case-Control Studies; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Retrospective Studies; Schizophrenia | 2004 |
Aripiprazole-associated dyskinesia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dyskinesia, Drug-Induced; Humans; Male; Piperazines; Psychotic Disorders; Quinolones | 2005 |
Pharmacokinetics of aripiprazole and concomitant lithium and valproate.
Topics: Adult; Aripiprazole; Drug Therapy, Combination; Humans; Lithium; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Valproic Acid | 2005 |
The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Child, Preschool; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Retrospective Studies; Treatment Outcome | 2004 |
Aripiprazole and depression in schizoaffective disorder.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Comorbidity; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2005 |
Increased efficacy with addition of clozapine to aripiprazole: alternative explanations.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2005 |
Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hospitalization; Humans; Male; Mathematical Computing; Middle Aged; Obesity; Piperazines; Product Surveillance, Postmarketing; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Schizophrenia; Treatment Outcome | 2005 |
Clozapine-induced hyperlipidemia resolved after switch to aripiprazole therapy.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cholesterol; Clozapine; Humans; Hypercholesterolemia; Hyperlipidemias; Male; Piperazines; Psychotic Disorders; Quinolones | 2005 |
Catatonia and psychosis in a patient with AIDS: treatment with lorazepam and aripiprazole.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Anxiety Agents; Anti-HIV Agents; Antipsychotic Agents; Aripiprazole; Catatonia; Humans; Lorazepam; Male; Piperazines; Psychotic Disorders; Quinolones | 2005 |
Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Delusions; Depressive Disorder, Major; Dyskinesia, Drug-Induced; Haloperidol; Humans; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2005 |
[Suicidal ideations and suicide attempts after starting on aripiprazole, a new antipsychotic drug].
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Suicide, Attempted; Thinking | 2005 |
Galactorrhea with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Galactorrhea; Humans; Piperazines; Psychotic Disorders; Quinolones | 2005 |
Use of aripiprazole for psychosis and agitation in dementia.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Female; Humans; Neuropsychological Tests; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Treatment Outcome | 2006 |
Treatment-emergent psychosis with aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Humans; Middle Aged; Piperazines; Psychoses, Substance-Induced; Psychotic Disorders; Quinolones | 2005 |
Atypical antipsychotics: special formulations for acute agitation.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Risperidone; Thiazoles | 2005 |
Manifestation of multiple sclerosis with paranoid-hallucinatory psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diet; Epilepsy, Generalized; Female; Hallucinations; Humans; Hypnotics and Sedatives; Hypothyroidism; Lorazepam; Magnetic Resonance Imaging; Multiple Sclerosis; Paranoid Disorders; Piperazines; Psychotic Disorders; Quinolones | 2006 |
Aripiprazole-induced extrapyramidal side effects in a patient with schizoaffective disorder.
Topics: Adult; Aripiprazole; Basal Ganglia Diseases; Dopamine Agonists; Female; Humans; Piperazines; Psychotic Disorders; Quinolones | 2006 |
Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Piperazines; Psychoses, Substance-Induced; Psychotic Disorders; Quinolones; Schizophrenia; Serotonin Agents; Treatment Outcome | 2007 |
[Suicidal ideations and suicide attempts after starting on aripiprazole, a new antipsychotic drug].
Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Piperazines; Psychotic Disorders; Quinolones; Sleep Wake Disorders; Suicide, Attempted | 2006 |
[Suicidal ideations and suicide attempts after starting on aripiprazole, a new antipsychotic drug].
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Psychotic Disorders; Quinolones; Sleep Wake Disorders; Suicide, Attempted | 2006 |
The acutely psychotic patient--assessment and initial management.
Topics: Acute Disease; Adolescent; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Cyclohexanols; Female; Humans; Male; Physicians, Family; Piperazines; Practice Guidelines as Topic; Psychotic Disorders; Quinolones; Referral and Consultation; Risk Assessment; Venlafaxine Hydrochloride | 2006 |
Benefits of combining aripiprazole to clozapine: three case reports.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Resistance; Drug Therapy, Combination; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia, Disorganized; Schizophrenia, Paranoid | 2006 |
Clozapine augmentation with aripiprazole for negative symptoms.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenia, Paranoid; Schizophrenic Psychology; Treatment Outcome | 2006 |
Aripiprazole use in a pregnant schizoaffective woman.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Lactation; Piperazines; Pregnancy; Pregnancy Complications; Psychotic Disorders; Quinolones | 2006 |
Aripiprazole associated with severe exacerbation of Parkinson's disease.
Topics: Antipsychotic Agents; Aripiprazole; Dyskinesia, Drug-Induced; Female; Humans; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinsonian Disorders; Piperazines; Psychotic Disorders; Quinolones | 2006 |
Aripiprazole use in individuals with intellectual disability and psychotic or behavioural disorders: a case series.
Topics: Adolescent; Aged; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Female; Humans; Intellectual Disability; Male; Mental Disorders; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenia, Paranoid | 2006 |
Neuroacanthocytosis: presenting with depression.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dystonia; Female; Humans; Piperazines; Psychotic Disorders; Quinolones | 2006 |
Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Tolerance; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Parkinson Disease; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Severity of Illness Index; Time Factors | 2006 |
Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Avoidance Learning; Biomarkers; Brain; Brain Chemistry; Catalepsy; Clozapine; Dopamine Agonists; Drug Evaluation, Preclinical; Haloperidol; Male; Piperazines; Prolactin; Proto-Oncogene Proteins c-fos; Psychotic Disorders; Quinolones; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Serotonin, 5-HT2; Serotonin Antagonists; Treatment Outcome | 2007 |
Psychosis in a patient with Fabry's disease and treatment with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Fabry Disease; Humans; Male; Piperazines; Psychotic Disorders; Quinolones | 2007 |
Diagnostic and therapeutic challenges in narcolepsy-related psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diagnosis, Differential; Female; Hallucinations; Humans; Narcolepsy; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia | 2006 |
Manic episode during treatment with aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Humans; Middle Aged; Piperazines; Psychotic Disorders; Quinolones | 2007 |
Datapoints: The ups and downs of dosing second-generation antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Dose-Response Relationship, Drug; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Thiazoles | 2007 |
Aripiprazole in human milk.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delusions; Female; Humans; Milk, Human; Piperazines; Psychotic Disorders; Quinolones | 2007 |
Aripiprazole and neuroleptic malignant syndrome.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Neuroleptic Malignant Syndrome; Piperazines; Psychotic Disorders; Quinolones | 2007 |
Neuroleptic malignant syndrome induced by low dose aripiprazole in first episode psychosis.
Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Diagnosis, Differential; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neuroleptic Malignant Syndrome; Neurologic Examination; Piperazines; Psychotic Disorders; Quinolones | 2007 |
Aripiprazole-induced obsessive-compulsive disorder: a report of 2 cases.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Carbamazepine; Female; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Psychotic Disorders; Quinolones; Trifluoperazine | 2007 |
Augmentation of clozapine treatment with aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2007 |
Aripiprazole and worsening of psychosis: a case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Disease Progression; Female; Humans; Piperazines; Psychotic Disorders; Quinolones; Recurrence | 2007 |
Psychotic episode associated with Bikram yoga.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome; Yoga | 2007 |
Successful treatment of catatonia with aripiprazole in an adolescent with psychosis.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Catatonia; Child Development Disorders, Pervasive; Child, Preschool; Female; Hospitalization; Humans; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones | 2007 |
Tolerability and efficacy of aripiprazole in a case of psychotic anorexia nervosa comorbid with epilepsy and chronic renal failure.
Topics: Adult; Anorexia Nervosa; Antipsychotic Agents; Aripiprazole; Comorbidity; Epilepsy; Female; Humans; Kidney Failure, Chronic; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2007 |
Aripiprazole: effectiveness and safety under naturalistic conditions.
Topics: Adult; Antipsychotic Agents; Anxiety; Aripiprazole; Female; Humans; Inpatients; Italy; Male; Middle Aged; Outpatients; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Recurrence; Retrospective Studies; Schizoid Personality Disorder; Schizophrenia, Paranoid; Schizotypal Personality Disorder; Sleep Initiation and Maintenance Disorders; Time Factors; Treatment Outcome | 2007 |
Aripiprazole is associated with early onset of Tardive Dyskinesia like presentation in a patient with ABI and psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain Injuries; Dyskinesia, Drug-Induced; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome; Withholding Treatment | 2008 |
Is aripiprazole the only choice of treatment of the patients who developed anti-psychotic agents-induced leucopenia and neutropenia? A case report.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Blood Cell Count; Dibenzothiazepines; Female; Humans; Leukopenia; Neutropenia; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Sulpiride | 2008 |
Change in sexual dysfunction with aripiprazole: a switching or add-on study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Ejaculation; Erectile Dysfunction; Female; Humans; Hyperprolactinemia; Libido; Male; Menstruation Disturbances; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Sex Characteristics; Sexual Dysfunction, Physiological; Surveys and Questionnaires | 2008 |
Acute dystonic reaction after initiating aripiprazole monotherapy in a 20-year-old man.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Dystonia; Humans; Male; Piperazines; Psychotic Disorders; Quinolones | 2008 |
Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Fasting; Feeding Behavior; Female; Glucose; Glucose Tolerance Test; Humans; Incidence; Insulin; Male; Middle Aged; Olanzapine; Piperazines; Prevalence; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Time Factors | 2008 |
Do dopamine partial agonists have partial efficacy as antipsychotics?
Topics: Antipsychotic Agents; Aripiprazole; Brain; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Humans; Mood Disorders; Piperazines; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Treatment Outcome | 2008 |
Aripiprazole-induced parkinsonism and its association with dopamine and serotonin receptor polymorphisms.
Topics: Adolescent; Alleles; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Parkinsonian Disorders; Piperazines; Polymorphism, Genetic; Psychotic Disorders; Quinolones; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Risk Factors | 2008 |
Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors.
Topics: Antipsychotic Agents; Aripiprazole; Binding Sites; Corpus Striatum; Dopamine Agents; Humans; Piperazines; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Substantia Nigra | 2001 |